AstraZeneca Adds Intellipharmaceutics To Seroquel Row

Law360, New York (May 25, 2011, 3:26 PM ET) -- AstraZeneca Pharmaceuticals LP hit Intellipharmaceutics Corp. with a suit Monday in New Jersey federal court, adding the company to the list of generic-drug makers accused of infringing a patent for schizophrenia and bipolar drug Seroquel XR.

AstraZeneca said Intellipharmaceutics sent a notice letter earlier this month disclosing that it had submitted an abbreviated new drug application to the U.S. Food and Drug Administration seeking approval to make and sell generic versions of Seroquel XR in a range of doses from 150 milligrams to 400 mg and...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required